The direct-to-consumer genetic testing fog
By Timothy Caulfield,
Policy Options
| 05. 25. 2017
There is a direct-to-consumer (DTC) genetic testing company that gives parents the opportunity to uncover their kids’ “hidden” talents. You can (allegedly) find out if your child has the genetic propensity for things like dancing, passion, intelligence, self-reflection and even teenage romance. The company suggests that this information is valuable because it “will help you take control and maximize the development of your child,” including personalizing “discipline strategies” and career guidance so you can maximize your “returns on your investments” (because, let’s face it, kids are a financial sinkhole).
This is all scientifically absurd, of course. And any product based on the principle of having your kids do what you tell them seems destined to disappoint. Has the marketing team ever met a teenager?
But, despite the lack of evidence, these kooky kinds of DTC services continue to proliferate and have become big business. In China, for example, there has been a rise in genetic testing as many parents take their kids to “talent detection” facilities in the hope of gleaning information to inform education and career decisions.
There...
Related Articles
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...